Metabolomics for clinical use and research in chronic kidney disease.
about
Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuriaDisease-syndrome combination modeling: metabolomic strategy for the pathogenesis of chronic kidney disease.Chemical Analysis of Astragali Complanati Semen and Its Hypocholesterolemic Effect Using Serum Metabolomics Based on Gas Chromatography-Mass Spectrometry.Elucidation of complexity and prediction of interactions in microbial communities.Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report.Untargeted mass spectrometry discloses plasma solute levels poorly controlled by hemodialysis.METLIN: A Technology Platform for Identifying Knowns and Unknowns.Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD.Monitoring wastewater for assessing community health: Sewage Chemical-Information Mining (SCIM).Metabolomic Alterations Associated with Cause of CKD.New perspectives on CKD-induced dyslipidemia.Serum Metabolomic Profiling of All-Cause Mortality: A Prospective Analysis in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study Cohort.Urine metabolomics insight into acute kidney injury point to oxidative stress disruptions in energy generation and H2S availability.Navigating T-Cell Immunometabolism in Transplantation.Associations of Plasma Amino Acid and Acylcarnitine Profiles with Incident Reduced Glomerular Filtration Rate.The Promise of Systems Biology for Diabetic Kidney Disease.The Warburg Effect in Diabetic Kidney Disease.The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.The metabolomic quest for a biomarker in chronic kidney disease
P2860
Q33893655-32885483-82E4-4AA1-B1AC-37529AB0D34EQ41459702-EF488899-4523-4BA4-A461-2D5F992B96CEQ41662786-79819F59-9C28-44F9-AE25-0FB202CFA55FQ45017953-4933CC7D-1775-4B9B-B242-BE588B6E2EC9Q46124690-82C0A140-484C-455C-8B0E-B1B731359AECQ46271397-17F7BB9B-B270-46A8-A77A-A160F6C271DAQ47554803-93AEB804-744C-4805-9DAA-40A6BAD80CB7Q47571217-74E72512-D8BA-4265-8EE2-EE2A1550CFE0Q47604834-88DBA346-38A4-4326-9081-0F7F3E49BEC6Q47710032-8B94656C-3F60-47B3-B415-F1C75C15B1FFQ47922360-7843057B-5E06-4341-BA99-16F48B5D015CQ49489722-ED36E2B9-7874-4087-9C7B-124C6FD92D89Q49632078-29628D75-9535-4F60-81C1-5AB4AF753447Q49990145-F43AFF18-66AD-4A4B-A049-F34EDA1EAF8DQ51412140-AB22C7B2-3391-450A-AC35-C88736A62302Q52341285-01D0EB01-6E79-49B7-80C0-2E97F630EE96Q52618381-46498A32-1836-4557-9384-939635C9FEA2Q52688968-D79AD9FF-5E7A-4B67-AD41-C68561B2D834Q55002257-0B4BBB8F-182B-4FC7-9B5F-729D56093741Q57053846-C502AE37-F304-4EC7-9B98-1E0F4A99FBAC
P2860
Metabolomics for clinical use and research in chronic kidney disease.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Metabolomics for clinical use and research in chronic kidney disease.
@en
type
label
Metabolomics for clinical use and research in chronic kidney disease.
@en
prefLabel
Metabolomics for clinical use and research in chronic kidney disease.
@en
P2860
P356
P1476
Metabolomics for clinical use and research in chronic kidney disease.
@en
P2093
Jerzy Adamski
P2860
P2888
P304
P356
10.1038/NRNEPH.2017.30
P407
P577
2017-03-06T00:00:00Z
P6179
1084129792